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The effect of Fc receptors on the regulation of the immune system is well known. In recent years, 
the so called “inhibitory receptor” FcγRIIb has been shown to be responsible for the clearance 
mechanism of the liver endothelium, such as clearance of viruses, bacteria, and small immune 
complexes (SIC). To model the mechanism of clearance via FcγRIIb, antibody-opsonized HIV-
like particles (Ab-HIV) were used. It was found that Ab-VLP were cleared considerably faster 
from circulation than VLP by FcγRIIb on LSEC and the effector mechanism of LSEC FcγRIIb 
was identified to be endocytosis. From these results, pathological small immune complexes 
which lead to autoimmune disorders were then studied. A standard treatment for many 
autoimmune disorders such as Systemic Lupus Erythematosus (SLE), glomerulonephritis, and 
Idiopathic Thrombocytopenic Purpura (ITP) is intravenous immunoglobulin G (IVIG), however 
its mechanism is largely unknown. Due to its efficacy and the role FcγRIIb in clearance of SIC, 
it was hypothesized that the mechanism of IVIG is through the function of the FcγRIIb receptor 
in order to further understand it in order to further its efficacy for future immunotherapies to treat 
autoimmune disorders. The effect of IVIG on isolated LSEC from humanized 2B-KIX mice 
showed an upregulation in the expression of FcγRIIb on the cells surface. Thus, it is clear that 
the mechanism of action of IVIG on the clearance of SIC from circulation is through the 
upregulation of FcγRIIb. Modulation of this receptor could lead to new immunotherapies that 
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Literature Review  
FcγRs are integral cell membrane glycoproteins with receptor type-specific distinguishing 
features. They are the cellular receptors for immunoglobulins and, in humans, consists of four 
major types, FcγRI(CD64), FcγRII(CD32), FcγRIII(CD16) and  FcγRI.1 Of these, the Fc 
receptors can be either activation or inhibitory receptors, which transmit their signals via 
immunoreceptor tyrosine-based activation (ITAM) or inhibitory motifs (ITIM), respectively.2 Of 
the inhibitory Fc receptors, FcγRIIb has been characterized as one of the key players in the 
balance of the immune system, as without negative regulators such as the inhibitory Fc receptors, 
the imbalanced immune response leads to autoimmunity and autoimmune disease.3 
Previous research in our lab has shown two remarkable, novel findings: first, that the receptor 
FcγRIIb is found most abundantly in the liver (Fig. 1) and that 90% of the liver‘s FcγRIIb is 
found on the surface of the liver sinusoidal endothelial cells (LSEC).4 These cells are responsible 
for the clearance function of the liver, including clearance of bacteria, viruses, and small immune 
 
1Nimmerjahn, Falk, and Jeffrey V. Ravetch. (2006). Fcγ Receptors: Old Friends and New Family Members. 
Immunity, Cell Press. www.sciencedirect.com/science/article/pii/S1074761305003833?via%3Dihub. 
2 Ravetch, Jeffrey V., and Lewis L. Lanier. (2000). Immune Inhibitory Receptors. Science, American Association 
for the Advancement of Science. 
3 Nimmerjahn, Falk, and Jeffrey V. Ravetch. (2006). Fcγ Receptors: Old Friends and New Family Members. 
Immunity, Cell Press. 
4 Ganesan, L. P., Kim, J., Wu, Y., Mohanty, S., Phillips, G. S., Birmingham, D. J., … Anderson, C. L. (2012). 
FcγRIIb on liver sinusoidal endothelium clears small immune complexes. Journal of immunology (Baltimore, Md. : 
1950), 189(10), 4981–4988. doi:10.4049/jimmunol.1202017 
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complexes (SIC). The LSECs do this via endocytosis, which they seem to be well equipped for 
due to their expression of endocytic receptors including scavenger receptors.5 6 7  
 
Figure 1: A. An ECL-developed immunoblot using rabbit anti-mouse RIIb antibody showing RIIb expression in 
molecular weight (kDa) in several tissue and cell lysates. B. Bar graph expressing the means and standard deviations 
of immunoblot-derived band densities, after factoring total organ weight for both RIIb isoforms and Syk from all 
organs (n=3 WT mice). The asterisks indicate that the expression levels of Syk and RIIb in spleen and liver, 
respectively, are statistically significantly different from the average of all other organs (P<0.001). (Ganesan, et al. 
2012). 
 
5 Yao, Z., Mates, J. M., Cheplowitz, A. M., Hammer, L. P., Maiseyeu, A., Phillips, G. S., … Ganesan, L. P. (2016). 
Blood-Borne Lipopolysaccharide Is Rapidly Eliminated by Liver Sinusoidal Endothelial Cells via High-Density 
Lipoprotein. Journal of immunology (Baltimore, Md. : 1950), 197(6), 2390–2399. doi:10.4049/jimmunol.1600702 
6 Elvevold, K. , Simon‐Santamaria, J. , Hasvold, H. , McCourt, P. , Smedsrød, B. and Sørensen, K. K. (2008), Liver 
sinusoidal endothelial cells depend on mannose receptor‐mediated recruitment of lysosomal enzymes for normal 
degradation capacity. Hepatology, 48: 2007-2015. doi:10.1002/hep.22527  
7 Sørensen, K. K., Simon‐Santamaria, J. , McCuskey, R. S. and Smedsrød, B. (2015). Liver Sinusoidal Endothelial 
Cells. In Comprehensive Physiology, R. Terjung (Ed.). doi:10.1002/cphy.c140078 
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Antibody opsonized HIV (ab-HIV) falls into the category of small immune complexes (SIC) as 
these complexes are the size appropriate for receptor-mediated endocytosis by LSEC.8 Our lab 
was focused on how neutralizing antibodies (NAbs) suppress HIV infection by accelerating viral 
clearance from blood circulation, in addition to neutralization. NAbs bind and inactivate viruses 
through their Fab regions.  Thus, NAbs block HIV attachment to target cells by interfering with 
the interaction between HIV and its cellular receptors, such as the CD4.9 
Research Significance 
In recent years, new insight on how the body eliminates SIC from the blood has come to light. It 
was long known that pathogenic SICs, which deposit in organs like the kidneys, cause 
inflammation and diseases, such as Systemic Lupus Erythematosus (SLE), glomerulonephritis 
and many other autoimmune disorders. Normally, the majority of SIC are eliminated harmlessly 
by the liver before they can crosslink and form large immune complex, which eventually deposit 
in kidneys, resulting in the clinical manifestations of SLE. In addition, intravenous 
immunoglobulinG (IVIG), is a common treatment for SLE as well as other autoimmune diseases 
such as idiopathic thrombocytopenic purpura. However, the mechanism of IVIG for SIC removal 
is largely unknown. Given that FcγRIIb is known to clear SICs, I hypothesized that IVIG 
upregulates the expression of FcγRIIb on the surface of LSECs.  
This project has broad relevance to public health in that it will define the novel mechanism 
mediated by FcγRIIb in liver endothelium to eliminate rapidly and efficiently the circulating 
 
8 Mayr, L. M., Su, B., & Moog, C. (2017). Non-Neutralizing Antibodies Directed against HIV and Their Functions. 
Frontiers in immunology, 8, 1590. doi:10.3389/fimmu.2017.01590 
9 Burton, D. Antibodies, viruses and vaccines. (2002). Nat Rev Immunol 2, 706–713 doi:10.1038/nri891 
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immune complexes that cause painful and debilitating autoimmune diseases. The outcome of 
these studies will improve our understanding of the mechanism of action of IVIG in vivo and 
present novel methods to increase the efficacy of IVIG or even innovate new antibody-based 
immunotherapy that works more effectively.   
Methodology 
To evaluate the clearance of antibody opsonized HIV (Abs-HIV) and understand the mechanism 
of IVIG, we obtained an engineered mouse strain expressing human rather than mouse FcγRIIb 
(2B-KIX: FcγRIIb-Knock-In; Xencor).  
To identify the organ responsible for the enhanced clearance of Ab-HIV, we quantified the organ 
distribution of intravenously infused mixtures of HIV immunoglobulin (HIVIG) and Alexa 594 
conjugated-virus-like-particle (594-VLP) following previously published protocols10 11. The 
liver, heart, lung, spleen, and kidney were harvested 10 minutes after infusion, after euthanizing 
the mice.  Approximately 100 mg of each organ was lysed in tissue cell lysis buffer and 
fluorescence intensity was determined using an EnspireTM multimode plate reader (Perkin 
Elmer). The percentage distribution of HIVIG-594 was calculated by factoring the total weight 
of each organ. 
 
10 Ganesan, L. P., Mohanty, S., Kim, J., Clark, K. R., Robinson, J. M., & Anderson, C. L. (2011). Rapid and 
efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS pathogens, 7(9), e1002281. 
doi:10.1371/journal.ppat.1002281 
11 Ganesan, L. P., Kim, J., Wu, Y., Mohanty, S., Phillips, G. S., Birmingham, D. J., … Anderson, C. L. (2012). 
FcγRIIb on liver sinusoidal endothelium clears small immune complexes. Journal of immunology (Baltimore, Md. : 
1950), 189(10), 4981–4988. doi:10.4049/jimmunol.1202017 
5 
 
To determine the efficacy of the FcγRIIb in the clearance of HIV, male, 12-week-old, 2B-KIX 
and FcγRIIb KO mice (n = 4) were both infused by tail vein with Ab-HIV prepared using 
5x1010 HIV-VLP and 50mg/kg of HIVIG. The HIV particles still in circulation were quantified 
at 30 seconds, 2, 3, 5, and 10 minutes using heparinized capillary tubes by taking blood samples 
via retro-orbital plexus. Blood obtained at each time point was diluted and the HIV p24 
concentration was determined as pg/mL using p24 ELISA (Zeptometrix).  
To determine the effects of IVIG on the function of the LSECs, the expression of FcγRIIb was 
quantified using flow cytometry. Fresh LSECs were prepared from 2B-KIX mice (n = 3) and 
treated with IVIG and BSA as a control. The concentration of IVIG and the in vitro treatment 
was defined by literature.12 13 14  
Table 1. 
 
Table 1 shows the plating technique for overnight treatment. Resting cells were suspended in DMEM F12 while 
IVIG treated cell and BSA cells were treated with their respective supplements at the same concentration in DMEM 
F12. The cells were incubated at 5% CO and 37 degrees C for 8 hours.  
 
12 Siragam, V., Crow, A. R., Brinc, D., …. Lazarus, A. H. (2006). Intravenous immunoglobulin ameliorates 
ITP via activating Fcg receptors on dendritic cells” 
13 Nagelkerke, S. Q., Dekkers, G., Kustiawan, I., … Kuijpers, T. W. (2014). Inhibition of FcγR-mediated 
phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. Blood, 
124(25), 3709-3718. 
14 Nagelkerke, S. Q., & Kuijpers, T. W. (2015). Immunomodulation by IVIg and the Role of Fc-Gamma 





Animals: Transgenic mice expressing human FcγRIIb, 2B-KIX, from Xencor were bred and 
maintained.  FcγRIIb knock-out mice in C57BL/6 background (Dr. Jeffrey Ravetch) were 
purchased from The Jackson Laboratory. All studies were approved by The Ohio State 
University Institutional Animal Care and Use Committee and all procedures were in accordance 
with their guidelines.  All surgery was performed under Isoflurane anesthesia, and all efforts 
were made to minimize suffering.   
Results 
To obtain purified LSEC preparations, two negative selection steps were taken, using F4/80 
microbeads and anti-CD45 microbeads, to remove Kupffer cells (KC) and other leukocytes, 
respectively, from liver cell suspensions. Then, a positive selection for CD146 cells yielded in a 
pure LSEC preparation (Fig 2). 
 
Figure 2. Flow cytometry dot-plots show that the purity of the isolated cells, as evidenced in panel A. Panel B 
compares the isotype with shows that the isolated cells express 2.4G2 and are F/80-, which have been previously 
determined to be LSEC markers. 
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In order to test the phenotype of purified LSEC from humanized mice, the specificity of anti-
human FcγRIIb mAb 4F515 labeled with fluor Alexa 594 was tested for specificity for human 
FcγRIIb using mouse B cell line (A20), a human B cell line (Raji), and a cell line that lacks FcγR 
(HEK) (Fig 3).  
 
Figure 3: A. Representative flow cytometric acquisition plot showing gated cell lines; namely, Raji (Panel A), A20 
(Panel B), and HEK (Panel C) in the first column; and two-color flow cytometric analysis of gated population for 
2.4G2 FITC plus 4F5 Alexa 594 in the second column. The results are representative of 4 different experiments and 
mice. In A-C, events from isotype controls are represented as blue dots and from primary antibodies as red dots. The 
average percentage of events showing single or double positive expression from three different experiments is 
indicated in respective quadrants. 
 
15 Su, W. T., Rutigliano, D. N., Gholizadeh, M. , Jarnagin, W. R., Blumgart, L. H. and La Quaglia, M. P. (2007), 
Hepatic metastasectomy in children. Cancer, 109: 2089-2092. doi:10.1002/cncr.22650 
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The presence of fenestrae is considered the gold standard morphologic feature distinguishing 
LSEC from other cells of the liver. LSEC purified by the triple immunomagnetic separation 
shown the typical fenestrae in the membrane by SEM (Fig 4).  
 
Figure 4. The picture shows the SEM image of LSEC from a 2B-KIX mouse. Arrows point fenestrae. Note folded 
and layered cell membranes of LSEC. The scale bar indicates 5µm.  
 
Ten minutes after infusions, HIV particles were recovered 86±9% in liver, 2.2±1.1% in lung, 
0.1±0.3% in spleen, 1.8±1.3% in kidney and 9.0±9% in blood circulation suggesting strongly 




Figure 5: The bar graph shows the distribution percentage of Ab-HIV to various organs including blood after 
factoring total organ weight ± SD from 3 different mice. The * represents a p value of 0.05 by students t-test. 
Compared to the FcRIIb KO mice, the 2B-KIX (humanized FcγRIIb) mice had less HIV 
particles in circulation at every time point over a period of 10 minutes, thus indicating that the 
FcγRIIb receptor is mediating the clearance of the HIV particles.  
 
Figure 6. Clearance kinetics showing disappearance of Ab-HIV from blood circulation of 2B-KIX mouse (red open 
circle) and FcγRIIb KO (black closed circle). The curve describes the HIV-VLP particle numbers in blood per 
mouse cleared over ten min time ± SD using data averaged from 4 different mice. Values of all significant 




With this knowledge of Ab-HIV being cleared via mechanism of the FcγRIIb receptor, it became 
clearer that IVIG must be clearing SIC via the same mechanism. After treatment of the cells with 





Figure 7. A: Expression of FcγRIIb on cells treated by IVIG overnight (blue) overlaid on control 
cells (n = 3). B: Expression of FcγRIIb on cells treated with BSA (control) overnight (blue) overlaid on control cells 
(n = 3). 
 
Conclusion 
It is clear that FcγRIIb is the leading mediator or clearance of viruses and SIC. This is seen 
through the efficacy of clearance of Ab-HIV. This conclusion can lead to multiple studies of 
clearance mediated by FcγRIIb, including that of pathological SIC which may cause a host of 
autoimmune disorders. The result of IVIG, a common drug used to treat a multitude of various 
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autoimmune disorders, used to treat LSEC led to an upregulation of FcγRIIb, implying that its 
mechanism of action is also through this receptor. Modulation of this receptor could lead to new 
immunotherapies that can more effectively clear HIV and SICs and be a treatment for many 
other autoimmune disorders. 
Contributions 
I have standardized the protocol to isolate pure LSECs from mice needed for the aforementioned 
experiments. Prior, there was no good way to purify LSEC from the liver of mice without 
contamination from other cells and loss of the majority of the LSEC. The method that I have 
standardized uses a triple immuno-magnetic cell separation, which uses microscopic magnets, 
called microbeads, that bind to unique receptors on the cells of the liver in order to separate them 
based on positive and negative selection, which ultimately produces a pure and enriched LSEC 
sample from each mouse liver. This current method yields, at most, 5 million LSECs per mouse, 
whereas previous methods would yield a mere 0.5- 1 million LSECs per mouse. A fully detailed 
protocol is attached in the Appendix Section.           
Additionally, I prepared the HIV-VLP via transfection of HEK cells for all experiments 
regarding the clearance mechanism of Ab-HIV. I also completed the overnight studies using 
IVIG independently.  
Future work  
Many future experiments need to be done to fully understand the mechanism of action of IVIG 
mediated clearance. First, the experiment needs to be repeated in order to collect the cells and 
evaluated them using RT-PCR. This will show, undeniably, the increase of gene expression for 
FcγRIIb. In addition, future experiments should include repeating with multiple concentrations 
12 
 
of IVIG to understand dosing requirements, comparison the SIC uptake by LSECs treated with 
and without IVIG, in vivo kinetic studies using IVIG treatment of SIC on WT mice and RIIb KO 
mice and repetition of all in vitro experiments with a human cell line that expresses the correct 



















Appendix A: Liver Dissociation Protocol to Obtain LSEC via Immunomagnetic Separation 
Note: Operate MACSmix Tube Rotator on permanent run at a speed of approximately 12 rpm. 
 
A. Liver dissociation protocol  
1. Prepare dissociation mix by pipetting 4.7 mL GentleMACS DMEM into a gentleMACS 
C Tube. 
i. Use ~200 uL of this GentleMACS DMEM to wash the inside of the following 
enzyme vials in order to ensure maximum enzyme volume.  
2. Add 200 μL Enzyme D solution, 100 µL Enzyme R solution, and 20 μL Enzyme A 
solution to the C tube. → dissociation mix (see appendix for aliquoting) 
3. Incubate dissociation mix for 30 minutes at 37 °C in an incubator or 15 minutes in a 
water bath. 
i. Get the mouse during this incubation and excise liver. 
4. Dissect liver from mouse 
i. Remove gallbladder with forceps before dissecting the mouse liver and resect 
connective tissue. 
5. Rinse liver with GentleMACS DMEM by placing in petri dish. 
6. Transfer liver into the C Tube containing the dissociation mix. 
7. Tightly close C Tube and attach it upside down onto the sleeve of the GentleMACS 
Dissociator. 
i. Ensure that the sample material is located in the area of the rotor/stator. 
ii. Close C Tube tightly beyond the first resistance. 
8. Run the GentleMACS Program m_liver_03.  
i. Repeat no more than 3 times 
ii. Ensure dissociation of all lobes 
9. After termination of the program, detach C Tube from the GentleMACS Dissociator. 
10. Incubate sample for 30 minutes at 37 °C under continuous rotation using the MACSmix 
Tube Rotator. 
i. Make the 1 X lysis buffer in this step 
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11. Attach C Tube upside down onto the sleeve of the GentleMACS Dissociator. 
12. Run the GentleMACS Program m_liver_04. 
13. After termination of the program, detach C Tube from the GentleMACS Dissociator. 
14. Pour the cell suspension to a MACS SmartStrainer (100 µm). 
15. Wash the filter with 5 mL GentleMACS DMEM with stable glutamine and P/S and add 
to the smart strainer. 
i. For maximum cell recovery, rinse the used C Tube with ~5 mL GentleMACS 
DMEM before transferring to filter. 
16. Discard the filter and centrifuge cell suspension at 60 × g for 5 minutes to pellet the 
hepatocytes. 
i. Collect the supernatant without disturbing the pellet at all. 
17. Centrifuge at 2600 RPM for 10 minutes to pellet the NPCs.  
i. Aspirate supernatant.  
18. Resuspend cells in 10 mL of 1X Red Blood Cell Lysis Solution  
19. Vortex for 5 seconds and incubate for 2 minutes at room temperature.  
20. Centrifuge at 2600 RPM for 10 minutes at room temperature to pellet NPCs.  
i. Aspirate supernatant completely.   
21. Resuspend the cell pellet in an appropriate buffer and proceed to further applications. 
 
B. Immunomagnetic Separation Protocol 
I. Magnetic Labeling: F4/80 Conjugated Microbeads   
1. Resuspend NPCs in 400 ul MACS buffer, keep cells on ice.  
2. Add 10 ul of F4/80 Conjugated Microbeads and incubate for 15 min. in 4°C (IN BEER 
COOLER, NOT ON ICE!) 
a. Wash by directly adding 10ml MACS buffer to primary antibody and mix 
b. Centrifuge cells at 2600rpm for 5 min. at 4°C. Aspirate supernatant 
3. To the pellet add 500ul of MACS buffer 
a. If cells are clumping it is ok to resuspend cells in 1ml of MACS buffer 
II. Magnetic Separation: F4/80+ and F4/80- Selection 
4. Place the LS column in the magnetic field  
a. Prongs/projections pointed towards you 
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5. Place an appropriately labelled collection tube (50 ml falcon tube) below the column 
6. Prepare the LS column (Cat #130-042-401) by rinsing with 3ml MACS buffer 
7. Place the 30um Pre-Separation Filter (Cat #120-002-220)  on top of the column 
a. Place another appropriately labelled collection tube below column (F4/80- 
selection). This fraction will contain LSECs, NK cells, dendritic cells, etc. 
8. Apply cells to pre-separation filter, allow the cells to enter the column when there is a 
meniscus in the column 
a. Do not let the column get dry.  
b. Wash the column 3 times with 3ml MACS buffer for a total of 9ml. Add the next 
3 ml when there is a slight meniscus on top of the magnetic part of the column 
c. Pipet MACS buffer slowly by touching the pipet to the wall of the pre-separation 
filter. Be careful not to induce any air bubbles.  
9. Cap “F4/80- selection” tube and centrifuge at 2600rpm for 5 min. at 4°C 
10. While tube is centrifuging, remove column from magnet and place in another 
appropriately labelled “F4/80+ selection”15 ml falcon tube and remove pre-separation 
filter 
a. Tube labelled “F4/80+ selection” will contain KCs 
11. To the “F4/80+ selection” tube, pipet 5ml MACS buffer into the column and immediately 
flush out the magnetically labeled cells by firmly pushing the plunger into the column 
12. Centrifuge “F4/80+ selection” tube at 2600rpm for 3 min. at 4°C and resuspend in 500ul 
MACS buffer and store on ice until you are ready to start the flow protocol 
a. Count cells this should be the KCs 
III. Magnetic Labeling: CD45 Microbeads  
13. Resuspend NPCs from the F4/80- selection in 200 ul of MACS buffer per 107 cells 
14. Add 10 ul of CD45 Microbeads (Cat #130-052-301) per 107 cells to the cell suspension 
above and incubate for 15 min. in 4°C (IN BEER COOLER, NOT ON ICE!) 
15. Wash cells + microbeads by adding 6ml MACS buffer 
a. Centrifuge at 2600 rpm for 5 min at 4°C 
b. Aspirate off supernatant 
16. Resuspend cells in 500ul of MACS buffer 
a. If cells are clumping it is ok to resuspend cells in 1ml of MACS buffer 
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IV. Magnetic Separation: CD45- Selection 
17. Place the LS column in the magnetic field  
a. Prongs/projections pointed towards you 
18. Place an appropriately labelled collection tube (50 ml falcon tube) below the column 
19. Prepare the LS column by rinsing with 3ml MACS buffer 
20. Place the 30um Pre-Separation Filter on top of the column 
21. Place another tube labelled “CD45- and F4/80-” selection below column (eluent)  
22. Apply cells to pre-separation filter 
23. Wash the column 3 times with 3ml MACS buffer for a total of 9ml 
24. Discard the column as we do not need CD45 + cells.  
25. Cap “CD45- and F4/80-” tube and centrifuge at 2600rpm for 3 min. at 4°C 
V. Magnetic Labeling: CD146 (LSEC) Microbeads  
26. Resuspend “F4/80- & CD45-” cells in 200 ul of MACS buffer per 107 cells 
27. Add 20 ul of CD146 (LSEC) Microbeads (Cat # 130-092-007 Miltenyi biotech) to the 
cell suspension above and incubate for 15 min. in 4°C (IN BEER COOLER, NOT ON 
ICE!) 
28. Wash cells + microbeads with 6ml MACS buffer 
a. Centrifuge at 2600 rpm for 3 min (if need longer can spin for 10 min) at 4°C 
b. Aspirate off supernatant 
29. Resuspend cells in 500ul of MACS buffer 
VI. Magnetic Separation: (1) F4/80-, CD45- and CD146- Selection (2) F4/80-, CD45- and 
CD146+ Selection 
30. Place the LS column in the magnetic field  
a. Prongs/projections pointed towards you 
31. Place an appropriately labelled collection tube (50 ml falcon tube) below the column 
32. Prepare the LS column by rinsing with 3ml MACS buffer 
33. Place the 30um Pre-Separation Filter on top of the column 
34. Place another tube labelled “F4/80- and CD45- and CD146-” 50 mL falcon tube below 
column 
35. Apply cells to pre-separation filter 
36. Wash the column 3 times with 3ml MACS buffer for a total of 9ml  
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37. Discard the tube labelled “F4/80- and CD45- and CD146-” selection  
38. Remove column from magnet and place in another appropriately labelled “F4/80- and 
CD45- and CD146+ selection”  
a. These are LSECs (F4/80- and CD45- and CD146+ selection)  
39. To the column add 5ml MACS buffer into the column and immediately flush out the 
magnetically labeled cells by firmly pushing the plunger into the column 
40. Centrifuge “F4/80- and CD45- and CD146+ selection” tube at 2600rpm for 3 min. at 4°C 
and resuspend in 500ul MACS buffer and store on ice.  Count cells this should be the 
LSECs 
41. If you are doing IF  
a. Pellet the cells at 2600rpm for 3 min and resuspend in 1 ml 4%PFA in PBS FACS 
(from 20%)/mice cells  
b. Incubate for 15 min ROOM TEMPRATURE  
c. Pellet the cells at 2500rpm for 3 min and resuspend in 1 ml PBS FACS  
d. Repeat step c 
e. Resuspend in PBS FACS 1 ml. Cover with aluminum foil. Store in 4C 
 
Appendix B: Reagent Preparation for Liver Dissociation Protocol  
Appendix: Reagent preparation 
1. Prepare Enzyme D by reconstitution of the lyophilized powder in the vial with 3 mL DMEM 
with stable glutamine and P/S at room temperature.  
i. Do not try to resuspend by pipetting or vortexing.  
ii. Invert vial after closing and wait 5–10 minutes to dissolve the pellet. 
iii. Enzyme D should be sterile filtered with a small syringe filter prior to aliquoting. 
iv.  Prepare aliquots of 200 uL to avoid repeated freeze-thaw-cycles. Store aliquots at –
20 °C.  
v. This solution is stable for 6 months after reconstitution.  
2. Prepare Enzyme R by reconstitution of the lyophilized powder in the vial with 2.7 mL of 
DMEM with stable glutamine and P/S at room temperature. 
18 
 
i. Prepare aliquots of 100 uL to avoid repeated freeze-thaw-cycles. Store aliquots at –
20 °C.  
ii. This solution is stable for 6 months after reconstitution. 
iii. Make sure to thoroughly mix this suspension immediately before withdrawing the 
required reaction volume! 
3. Prepare Enzyme A by reconstitution of the lyophilized powder in the vial with 1 mL DMEM 
with stable glutamine and P/S at room temperature. 
i. Do not vortex.  
ii. Prepare aliquots of 20 uL to avoid repeated freeze-thaw-cycles. Store aliquots at –20 
°C.  
iii. This solution is stable for 6 months after reconstitution. 
4. Preparation of 1× Red Blood Cell Lysis Solution  
i. Dilute Red Blood Cell Lysis Solution (10×) 1:10 with double distilled water 
(ddH₂O), for example, dilute 1 mL of Red Blood Cell Lysis Solution (10×) with 9 
mL of ddH₂O.  
ii. Do NOT dilute with deionized water. 
iii. Store the prepared 1× Red Blood Cell Lysis Solution at room temperature.  
iv. Discard unused solution at the end of the day. 
5. Preparation of GentleMACS DMEM 
i. Start with incomplete DMEM 
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Figure 1: A. An ECL-developed immunoblot using rabbit anti-mouse RIIb antibody showing RIIb expression in 
molecular weight (kDa) in several tissue and cell lysates. B. Bar graph expressing the means and standard deviations 
of immunoblot-derived band densities, after factoring total organ weight for both RIIb isoforms and Syk from all 
organs (n=3 WT mice). The asterisks indicate that the expression levels of Syk and RIIb in spleen and liver, 





Figure 2. Flow cytometry dot-plots show that the purity of the isolated cells, as evidenced in panel A. Panel B 
compares the isotype with shows that the isolated cells express 2.4G2 and are F/80-, which have been previously 
determined to be LSEC markers. 
 
Figure 3: A. Representative flow cytometric acquisition plot showing gated cell lines; namely, Raji (Panel A), A20 
(Panel B), and HEK (Panel C) in the first column; and two-color flow cytometric analysis of gated population for 
2.4G2 FITC plus 4F5 Alexa 594 in the second column. The results are representative of 4 different experiments and 
mice. In A-C, events from isotype controls are represented as blue dots and from primary antibodies as red dots. The 
average percentage of events showing single or double positive expression from three different experiments is 




Figure 4. The picture shows the SEM image of LSEC from a 2B-KIX mouse. Arrows point fenestrae. Note folded 
and layered cell membranes of LSEC. The scale bar indicates 5µm.  
 
Figure 5: The bar graph shows the distribution percentage of Ab-HIV to various organs including blood after 





Figure 6. Clearance kinetics showing disappearance of Ab-HIV from blood circulation of 2B-KIX mouse (red open 
circle) and FcγRIIb KO (black closed circle). The curve describes the HIV-VLP particle numbers in blood per 
mouse cleared over ten min time ± SD using data averaged from 4 different mice. Values of all significant 
correlations (p<0.05) are given with degree of significance indicated (* p<0.05, ** p<0.01, *** p<0.001) by 
student's t-test. 
 
Figure 7. A: Expression of FcγRIIb on cells treated by IVIG overnight (blue) overlaid on control 
cells (n = 3). B: Expression of FcγRIIb on cells treated with BSA (control) overnight (blue) overlaid on control cells 
(n = 3). 
 
